Turkish Journal of Hematology Volume: 35 - Issue: 4

Benli A, et al: Piperacillin-Tazobactam Myelosuppression
Turk J Hematol 2018;35:290-295
Table 3. Characteristics of the 18 episodes of leukopenia.
Sex Age, year Time to onset of leukopenia, day Total dose, g Initial leukocytes count,
x10 9 /L
Nadir of leukocytes count,
x10 9 /L
F 34 15 180 11.7 2.7
F 76 17 204 5.7 3.7
M 47 10 120 8.9 3.4
F 70 8 96 7.2 3.2
M 46 30 360 13.8 3.2
F 40 15 180 9.8 2.6
M 30 25 300 8.0 3.9
M 69 21 252 7.3 3.2
M 73 21 252 11.8 3.4
M 63 33 396 11.9 3.1
F 60 20 240 6.6 3.4
M 70 29 348 5.2 3.8
M 69 40 480 4.8 3.9
M 22 14 168 6.9 3.1
M 51 20 240 8.0 2.3
M 60 20 240 6.9 3.9
M 32 23 276 6.4 3.8
F
Mean ± SD
18
51.66±18.72
21
21.22±8.04
SD: Standard deviation, M: male, F: female.
252
254.66±96.48
15.9
8.71±3.12
3.9
3.36±0.48
Table 4. Characteristics of the 11 episodes of neutropenia.
Sex Age, year Time to onset of
neutropenia, day
Total dose, g
Initial neutrophils count,
x10 9 /L
Nadir of neutrophiles count,
x10 9 /L
M 60 25 300 9.9 0.8
M 47 10 120 6.4 0.5
F 70 8 96 6.2 1.4
M 46 30 360 10.5 1.1
M 73 23 276 9.4 1.2
M 63 24 288 8.1 0.8
F 60 20 240 4.3 1.9
M 51 21 252 3.7 1.3
M 60 23 276 4.5 1.9
F 18 21 252 11.0 1.6
F 19 6 72 9.7 1.5
Mean ± SD 51.54±18.39 19.18±7.7 230.18 ±92.45 7.6±2.68 1.27±0.45
SD: Standard deviation, M: male, F: female.
antibiotic therapy with TZP should be limited to patients with
severe life-threatening Pseudomonas aeruginosa infections and
especially those with immunocompromising conditions because
of the increased rate of adverse effects, including leukopenia,
and the lack of evidence of either improved efficacy or decreased
resistance [12].
Study Limitations
Our study is novel in several ways: it includes the largest patient
sample among studies on the same subject, we evaluated the
hematologic adverse effects of TZP as a whole, and finally
we analyzed the independent risk factors for development of
leukopenia, neutropenia, and eosinophilia.
294